Efficacy of Tadalafil (5mg) For Treatment of Early Storage Symptoms and Erectile Dysfunction After Endoscopic Enucleation of Prostate
Key facts
- Who runs it
- Mansoura University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 110 people, planned
- Started
- 1 Apr 2023
- Planned end
- Jul 2025
- Type of study
- Interventional, 2 groups
- Treatments tested
- Tadalafil 5mg / Placebo
- Record updated
- 11 June 2025
Who can take part
- Age
- 40 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Patients' age ≥ 40 years
- LUTS secondary to BOO due to BPH who failed medical treatment
- International prostate symptom scores (IPSS) >15 and bother score (QOL) ≥ 3 (according to IPSS question 8)
- Peak urinary flow rate (Qmax) <15 ml/sec
- ASA (American society of anaesthesiologists) score ≤ 3
- Sexually active men, not receiving PDE5I
Who cannot take part
- Patients with unstable angina pectoris, recent myocardial infarction or stroke myocardial insufficiency
- Patients with severe hepatic or renal insufficiency
- Patients with uncontrolled diabetes mellitus or neurologic condition(eg. parkinsoism)
- Patients using nitrates, potassium channel opener, or α1-blockers doxazosin and terazosin for control of hypertension
- Patients who are sexually inactive
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 80 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
From previous studies, the investigators found that sexual outcomes after prostate surgery may show insignificant improvement, remain unchanged or deteriorate in non-negligible number of patients especially those with high preoperative IIEF scores. Deterioration of erectile function could be attributed to persistence of storage symptoms specially nocturia. Several pathophysiologic mechanisms, described before, are involved in pathogenesis of LUTS and ED and one can imagine that after relief of obstruction, the erectile function should improve, however lack of improvement or even deterioration suggests that damage associated with these mechanisms is irreversible and patients may require some sort of penile rehabilitation after surgery.
Read full original descriptionShow less
The investigators hypothesized that Tadalafil may enhance relief of storage symptoms and enhance recovery of erectile function after surgery for BPH. With this assumption, a RCT was designed to examine the utility and efficacy of Tadalafil, once daily dose, to relieve persistent/ de novo storage symptoms and early erectile function deterioration after endoscopic prostate surgery.
The 2 groups in the trial
- Tadalafil 5 mg dailyTreatment being tested
those patients will receive Tadalafil 5 mg daily after HoLEP
Treatment: Tadalafil 5mg / Placebo
- PlaceboTreatment being tested
Those patients will receive Placebo after HoLEP
Treatment: Tadalafil 5mg / Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized Controlled Trial to Examine the Utility of Tadalafil (5mg) For Treatment of Early Storage Symptoms and Erectile Dysfunction After Anatomical Endoscopic Enucleation of Prostate (AEEP)
- Criteria questions
- Built from NCT05955001, who can take part
- Record updated
- 11 June 2025